

Gupta V, Singh E, Sharma S. Biomarkers: A comprehensive review. *Bull. Pharm. Res.* 2014; 4(1):58-66.

References (28):

1. Bishop JM. The molecular genetics of cancer. *Science* 1987;235(4786):305-11.
<http://www.sciencemag.org/content/235/4786/305.abstract>
2. Crowell RE, Gilliland FD, Temes RT, Harms HJ, Neft RE, Heaphy E, Auckley DH, Crooks LA, Jordan SW, Samet JM, Lechner JF, Belinsky SA. Detection of trisomy 7 in nonmalignant bronchial epithelium from lung cancer patients and individuals at risk for lung cancer. *Cancer Epidemiol. Biomarkers Prev.* 1996;5(8):631-7.
<http://www.ncbi.nlm.nih.gov/pubmed/8824366>
3. Esteller M, Catusas L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB, Herman JG. *Am. J. Pathol.* 1999;155(5):1767-72.
<http://www.ncbi.nlm.nih.gov/pubmed/10550333>
4. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. *Cancer Res.* 1999;59(1):67-70.
<http://www.ncbi.nlm.nih.gov/pubmed/9892187>
5. Fenech, M. Chromosomal biomarkers of genomic instability relevant to cancer. *Drug Discov. Today* 2002;7(22):1128-37.
<http://www.ncbi.nlm.nih.gov/pubmed/12546856>
6. Gillatt D, Reynard JM. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. *Br. J. Urol.* 1995; 75(3):341-6.
<http://www.ncbi.nlm.nih.gov/pubmed/7537603>
7. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson D, Mills GB. Specific keynote: genome copy number abnormalities in ovarian cancer. *Gynecol. Oncol.* 2003;88(1.2):S16-21.
<http://www.ncbi.nlm.nih.gov/pubmed/12586079>
8. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N. Engl. J. Med.* 2003;349(21):2042-54.
<http://www.ncbi.nlm.nih.gov/pubmed/14627790>
9. Karley D, Gupta D, Tiwari A. Biomarker for cancer: A great promise for future. *World J. Oncol.* 2011;2(4):151-7.
<http://www.wjon.org/index.php/wjon/article/view/352/258>

10. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. *Clin. Cancer Res.* 2004;10(11):3927-33.
<http://www.ncbi.nlm.nih.gov/pubmed/15173102>
11. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: Insights into etiology, pathogenesis and prevention from The Gambia, West Africa. *Carcinogenesis* 2006;27(10):2070-82.
<http://www.ncbi.nlm.nih.gov/pubmed/16679307>
12. Liu C, Tsao MS. In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas. *Am. J. Pathol.* 1993;142(4):1155-62.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1886862/>
13. Loukopoulos P, Thornton JR, Robinson WF. Clinical and pathologic relevance of p53 index in canine osseous tumors. *Vet. Pathol.* 2003;40(3):237-48.
<http://www.ncbi.nlm.nih.gov/pubmed/12724563>
14. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. *Nat. Rev. Cancer* 2005;5(11):845-56.
<http://www.ncbi.nlm.nih.gov/pubmed/16239904>
15. Manne U, Srivastava R-G, Srivastava S. Recent advances in biomarkers for cancer diagnosis and treatment. *Drug Discov. Today* 2005;10(14):965-76.
<http://www.ncbi.nlm.nih.gov/pubmed/16023055>
16. Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. *Cancer* 1988;83(12):2456-67.
<http://www.ncbi.nlm.nih.gov/pubmed/9874449>
17. Naylor S. Biomarkers: current perspectives and future prospects. *Expert Rev. Mol. Diagn.* 2003;3(5):525-9.
<http://www.ncbi.nlm.nih.gov/pubmed/14510173>
18. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. *J. Natl. Cancer Inst.* 1999;91(23):2001-8.
<http://www.ncbi.nlm.nih.gov/pubmed/10580024>
19. Sahu P, Pinkalwar N, Dubey RD, Paroha S, Chatterjee S, Chatterjee T. Biomarkers: An emerging tool for diagnosis of a disease and drug development. *Asian J. Res. Pharm. Sci.* 2011;1(1):9-16.
www.asianpharmaonline.org/AJPS/3_AJPS_1_1_2011.pdf

20. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. *Cancer Res.* 1993;53(8):1906-10.
<https://scholars.duke.edu/display/pub679703>
21. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. *Clin. Cancer Res.* 2007;13(7):2023-9.
<http://www.ncbi.nlm.nih.gov/pubmed/17404082>
22. Silverman P. Cancer overview. *NetWellness* Friday, July 4, 2014.
<https://www.netwellness.org/healthtopics/cancer/canceroverview.cfm>
23. Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. *Leuk. Res.* 2010;34(3):399-402.
<http://www.ncbi.nlm.nih.gov/pubmed/19781774>
24. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihnsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. *J. Natl. Cancer Inst.* 1992;84(11):845-55.
<http://www.ncbi.nlm.nih.gov/pubmed/1317462>
25. Tlsty TD, Briot A, Gualberto A, Hall I, Hess S, Hixon M, Kuppaswamy D, Romanov S, Sage M, White A. Genomic instability and cancer. *Mutat. Res.* 1995; 337(1):1-7.
<http://www.ncbi.nlm.nih.gov/pubmed/7596354>
26. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. *Dis. Markers* 2002;18(2):41-6.
<http://www.ncbi.nlm.nih.gov/pubmed/12364809>
27. Wagner PD, Maruvada P, Srivastava S. Molecular diagnostics: a new frontier in cancer prevention. *Expert Rev. Mol. Diagn.* 2004;4(4):503-11.
<http://www.ncbi.nlm.nih.gov/pubmed/15225098>
28. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD, Gazdar AF. Molecular damage in the bronchial epithelium of current and former smokers. *J. Natl. Cancer Inst.* 1997;89(18):1366-73.
<http://www.ncbi.nlm.nih.gov/pubmed/9308707>